首页> 美国卫生研究院文献>other >The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs
【2h】

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs

机译:外周血中性粒细胞与淋巴细胞比是用EGFR-TKIs治疗的EGFR突变型非小细胞肺癌患者生存的预后指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment for EGFR-mutant nonsmall cell lung cancer (NSCLC) patients. However, studies have reported that not all NSCLC patients harboring kinase domain mutations in epidermal growth factor receptor (EGFR) show significant clinical benefits from EGFR-targeted tyrosine kinase inhibitors (TKIs). Therefore, it is necessary to establish feasible biomarkers to predict the prognosis of EGFR-mutant NSCLC patients treated with EGFR-TKIs. This study aimed to determine biomarkers using inflammatory parameters from complete blood counts to predict the prognosis of EGFR-mutant NSCLC patients treated with EGFR-TKIs.We retrospectively investigated 127 stage IIIB/IV NSCLC patients with activating EGFR mutations who were treated with EGFR-TKIs. We used receiver operating characteristic (ROC) curves to determine the optimal cut-off for the inflammatory markers as prognostic factors. Additionally, univariate and multivariate analyses were used to identify prognostic factors for progression-free survival (PFS) and overall survival (OS) of EGFR-mutant NSCLC patients treated with EGFR-TKIs.The receiver operating characteristic analysis indicated that the lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) cut-off values were 3.37 and 2.90, respectively. The univariate analysis showed that a high LMR (>3.37) and low NLR (≤2.90) were significantly correlated with long-term PFS and OS (LMR, P = .007; NLR, P < .001). The multivariate Cox regression analysis revealed that only low NLR was an independent prognostic factor for long-term PFS and OS (PFS, HR = 0.573, 95% CI: 0.340–0.964, P = .036; OS, HR = 0.491, 95% CI: 0.262–0.920, P = .026).The data show that a low NLR was a good prognostic factor in EGFR-mutant NSCLC patients receiving EGFR-TKIs treatment. Moreover, the NLR measurement has better prognostic value than LMR.
机译:表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)是EGFR突变型非小细胞肺癌(NSCLC)患者的标准一线治疗方法。但是,研究报告表明,并非所有在表皮生长因子受体(EGFR)中具有激酶结构域突变的NSCLC患者都显示出以EGFR为靶点的酪氨酸激酶抑制剂(TKI)的显着临床益处。因此,有必要建立可行的生物标志物以预测用EGFR-TKIs治疗的EGFR突变NSCLC患者的预后。这项研究旨在利用全血细胞计数中的炎症参数来确定生物标志物,以预测用EGFR-TKIs治疗的EGFR突变NSCLC患者的预后。我们回顾性调查了127例用EGFR-TKIs治疗的EGFR激活突变的IIIB / IV期NSCLC患者。我们使用接收器操作特征(ROC)曲线来确定炎症标志物的最佳临界值作为预后因素。此外,使用单因素和多因素分析来确定接受EGFR-TKI治疗的EGFR突变NSCLC患者的无进展生存期(PFS)和总体生存期(OS)的预后因素。单核细胞比率(LMR)和中性白细胞与淋巴细胞比率(NLR)的截断值分别为3.37和2.90。单变量分析表明,高LMR(> 3.37)和低NLR(≤2.90)与长期PFS和OS显着相关(LMR,P = .007; NLR,P <.001)。多元Cox回归分析显示,只有低NLR是长期PFS和OS的独立预后因素(PFS,HR = 0.573,95%CI:0.340-0.964,P = 0.036; OS,HR = 0.491,95% CI:0.262–0.920,P = .026)。数据显示,在接受EGFR-TKIs治疗的EGFR突变NSCLC患者中,低NLR是良好的预后因素。此外,NLR测量比LMR具有更好的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号